Contact information
Emma Francis né Callen
Clinical Trials Support Officer/ Play Assistant
Emma Francis joined the Oxford Vaccine Group in June 2017; as a Clinical Trials Play and Study Assistant.
In July 2018 she advanced to the position of Clinical Trials Support Officer/ Play Assistant where she assists the academic research staff in the planning and running of clinical trials. Emma is responsible for the day to day administration of specific research studies, involving carrying out various office duties and study-related tasks
Her role as a Play Assistant is to accompany doctors and nurses on home visits to children of different ages, providing them with the relevant form of distraction and play in order to provide some therapy and comfort during any venepuncture and immunisation procedures.
She has nearly 20 years experience with working with children and has a level 3 Btec National Diploma in Childcare.
Recent publications
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
-
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Journal article
Flaxman A. et al, (2021), Lancet, 398, 981 - 990
-
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article
Barrett JR. et al, (2021), Nat Med, 27
-
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article
Ewer KJ. et al, (2021), Nat Med, 27
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891